Skip to main content
. 2023 May 30;15(11):2976. doi: 10.3390/cancers15112976

Table 3.

Comparisons of thyroglobulin, TSH at multiple time points and 131I administered activity among five groups of patients.

ND
Median (95%CI)
(Min to Max)
DD
Median (95%CI)
(Min to Max)
R
Median (95%CI)
(Min to Max)
NED-I
Median (95%CI)
(Min to Max)
NED-L
Median (95%CI)
(Min to Max)
p
Tg−30 (ng/mL) 3.50 (1.62 to 5.00)
(1.30 to 8.60)
28.80 (16.00 to 189.00)
(16.00 to 189.00)
1.50 (0.40 to 2.93)
(0.30 to 2.93)
0.47 (0.30 to 0.64)
(0.09 to 1.50)
0.48 (0.30 to 0.63)
(0.00 to 1.45)
<0.0001
Tg0 (ng/mL) 15.26 (5.92 to 38.43)
(0.97 to 64.00)
159.40 (33.00 to 2095.00)
(33.00 to 2095.00)
7.82 (0.98 to 149.00)
(0.61 to 149.00)
1.38 (0.59 to 2.20)
(0.00 to 25.31)
1.59 (0.43 to 3.08)
(0.00 to 81.90)
<0.0001
Tg0H 33.70 (2.49 to 64.00)
(2.49 to 64.00)
359.00 (159.40 to 2095.00)
(159.40 to 2095.00)
74.99 (0.98 to 149.00)
(0.49 to 149.00)
1.97 (0.30 to 6.54)
(0.00 to 14.68)
2.73 (1.33 to 4.80)
(0.00 to 39.80)
0.002
Tg0TSH 7.41 (0.97 to 38.43)
(0.97 to 38.43)
59.24 (33.00 to 85.49)
(33.00 to 85.49)
7.15 (0.61 to 20.32)
(0.61 to 20.32)
0.59 (0.00 to 3.07)
(0.00 to 25.31)
0.44 (0.23 to 3.08)
(0.00 to 81.90)
0.004
p 0.11 0.15 0.84 0.21 0.08
Tg+7 (ng/mL) 82.00 (40.00 to 308.50)
(0.69 to 515.00)
169.70 (100.00 to 900.00)
(100.00 to 900.00)
13.70 (1.91 to 211.20)
(1.91 to 211.20)
23.81 (5.60 to 50.60)
(0.00 to 99.40)
18.58 (7.39 to 37.00)
(0.00 to 872.00)
0.005
Tg+7H 85.95 (40.00 to 515.00)
(40.00 to 515.00)
534.85 (169.70 to 900.00)
(169.70 to 900.00)
139.50 (88.00 to 191.00)
(88.00 to 191.00)
33.85 (4.43 to 96.50)
(0.00 to 99.40)
36.40 (6.39 to 78.70)
(0.00 to 283.00)
0.036
Tg+7TSH 78.99 (0.69 to 183.00)
(0.69 to 183.00)
100.00 (100.00 to 100.00)
(100.00 to 100.00)
11.46 (1.91 to 211.20)
(1.91 to 211.20)
18.42 (0.54 to 50.60)
(0.00 to 211.20)
12.80 (5.12 to 35.00)
(0.00 to 872.00)
0.37
p 0.08 0.54 0.33 0.24 0.36
TSH−30 (mIU/L) 0.49 (0.13 to 0.80)
(0.00 to 0.87)
0.50 (0.08 to 1.26)
(0.08 to 1.26)
0.45 (0.07 to 1.35)
(0.04 to 1.35)
0.11 (0.09 to 0.25)
(0.00 to 0.71)
0.17 (0.12 to 0.21)
(0.00 to 1.34)
0.14
TSH0 (mIU/L) 101.67 (79.29 to 138.38)
(26.51 to 160.97)
102.86 (64.30 to 244.41)
(64.30 to 244.41)
171.61 (79.34 to 498.00)
(43.33 to 498.00)
106.59 (82.74 to 121.00)
(36.20 to 232.43)
98.59 (84.18 to 116.10)
(20.28 to 299.23)
0.32
Activity (mCi) 120 (100 to 120)
(30 to 150)
150 (100 to 150)
(100 to 150)
100 (80 to 150)
(50 to 150)
100 (100 to 120)
(50 to 120)
80 (80 to 100)
(50 to 150)
<0.0001
Activity (MBq) 4440 (3700 to 4440)
(1110 to 5550)
5550 (3700 to 5550)
(3700 to 5550)
3700 (2960 to 5550)
(1850 to 5550)
3700 (1850 to 4440)
(3700 to 4440)
2960 (2960 to 3700)
(1850 to 5550)
<0.0001

Abbreviations: ND = hodal disease; DD = distant disease; R = biochemical indeterminate—minimal residual tissue; NED-I = non-evidence of disease—ATA intermediate risk; NED-L = non-evidence of disease—ATA low risk Tg−30 = thyroglobulin 30 days before 131I; Tg0 = thyroglobulin at 131I; Tg0H = Tg in hypothyroidism; Tg0TSH = Tg after rhTSH; Tg+7 = thyroglobulin 7 days after 131I; Tg+7H = Tg in hypothyroidism 7 days after 131I; Tg+7TSH = Tg after rhTSH 7 days after 131I; TSH−30 = thyrotropin before 131I; TSH0 = thyrotropin at 131I. Post hoc analysis: Tg−30 = (ND vs. DD), p = 0.009; (ND vs. NED-I), p < 0.0001; (ND vs. NED-L), p < 0.0001; (DD vs. R), p = 0.03; (DD vs. NED-I), p = 0.004; (DD vs. NED-L), p = 0.002; Tg0 = (ND vs. DD) p = 0.03; (ND vs. NED-I) p = 0.0004; (ND vs. NED-L) p = 0.0007; (DD vs. NED-I) p = 0.004; (DD vs. NED-L) p = 0.002; Tg0H = (ND vs. NED-I) p = 0.02; (ND vs. NED-L) p = 0.036; (DD vs. NED-L) p = 0.038; Tg0TSH = (ND vs. DD) p = 0.0007; (DD vs. R) p = 0.0002; (DD vs. NED-I) p < 0.0001; (DD vs. NED-L) p < 0.0001; Tg+7 = (ND vs. NED-I) p = 0.02; (ND vs. NED-L) p = 0.035; (DD vs. NED-I) p = 0.04; Tg+7H = (ND vs. DD) p = 0.01; (DD vs. NED-I) p = 0.0001; (DD vs. NED-L) p < 0.0001; Activity = (ND vs. NED-L) p = 0.001; (DD vs. NED-L) p = 0.007; (NED-I vs. NED-L) p = 0.0001.